Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tersolisib - Eli Lilly and Company

Next Previous
Drug Profile

Tersolisib - Eli Lilly and Company

Alternative Names: LY-4064809; ST-814; STX-478; STX-H1047-PI3Ka inhibitors - Eli Lilly and Company

Latest Information Update: 30 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scorpion Therapeutics
  • Developer Eli Lilly and Company
  • Class Amides; Amines; Antineoplastics; Benzofurans; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Solid tumours
  • Preclinical Colorectal cancer

Most Recent Events

  • 01 Jul 2026 Eli Lilly and Company initiates enrolment in a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT07662798)
  • 23 Jun 2026 Eli Lilly and Company plans a phase I PK trial for Healthy volunteers in USA (PO) in July 2026 (NCT07662798)
  • 02 Jun 2026 Efficacy, adverse event and pharmacokinetics data from phase the I/II PIKALO-1 trial in Breast cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top